Are President Trump and his healthcare policy advisors getting hoodwinked by Big Pharma on drug price reform?

About The Podcast:

Millions of Americans feel confused and frustrated in their search for quality healthcare coverage.

Between out-of-control costs, countless inefficiencies, a lack of affordable universal access, and little focus on wellness and prevention, the system is clearly in dire need of change.

Hosted by healthcare policy and technology expert Marc S. Ryan, the Healthcare Labyrinth Podcast offers accessible, incisive deep dives on the most pressing issues and events in American healthcare.

Marc seeks to help Americans become wiser consumers and navigate the healthcare maze with more confidence and certainty through The Healthcare Labyrinth website and his book of the same name.

Marc is an unconventional Republican who believes that affordable universal access is a wise and prudent investment. He recommends common-sense solutions to reform American healthcare.

Tune in every week as Marc examines the latest developments in the space, offering analysis, insights, and predictions on the changing state of healthcare in America.

About The Episode:

On this episode, Marc discusses drug price reform and asks if President Trump and his healthcare policy advisors are getting hoodwinked by Big Pharma.

Key Takeaways:

Are President Trump and his healthcare policy advisors getting hoodwinked by Big Pharma on drug price reform?

President Trump has come out swinging in Trump 47 on drug price reform and I applaud that.

He has shown a good understanding of the drug price system and what needs to be done to reform it.

He is using all sorts of ways to cajole and even extort concessions from Big Pharma. It is admirable.

He has proposed the most favored nation form of drug pricing, where America would adopt the lowest price on each brand drug anywhere in the developed world.

But Trump could back off aggressive reforms based on proposed concession deals from brand drug companies.

These deals do not amount to fundamental drug price reform, but window-dressing and efforts by Big Pharma at self-preservation.

The targeted reforms do not fundamentally change price for the vast majority of consumers or the system as a whole.

Trump should stick to his game plan and truly reform drug price.

Connect With Marc:

Marc on LinkedIn

Marc on Twitter

THL Podcast

Resources:

THL’s Newsfeed

THL’s Blog

The Healthcare Labyrinth: A Guide to Navigating Health Plans and Fixing American Health Insurance